Table 3 Most common treatment-related adverse events

From: Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial

 

Grade 1/2

Grade 3/4

Toxicity

No.

%

No.

%

Anaemia

9

37

2

8

Neutropenia

3

12

10

42

Febrile neutropenia

0

0

2

8

Diarrhoea

3

12

3

13

Sensory neuropathy

7

29

3

13

Fatigue

9

37

2

8

Hand–foot syndrome

7

29

7

29

Back to article page